Goldline Pharmaceutical files SEBI Reg 29(2) disclosure for Swapan Khandelwal

What Goldline Pharmaceutical announced

On 24 June 2026 Goldline Pharmaceutical Ltd (BSE: 544759) submitted a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing relates to an acquisition of shares by an individual named Swapan Khandelwal. Apart from the name of the acquirer, the notice does not provide any quantitative details such as the number of shares bought, the price paid, or the percentage of the company's equity that has changed hands.

Regulation 29(2) disclosure – what it means

Regulation 29(2) requires any person who acquires shares that could potentially give them control of a listed entity to inform the stock exchange. The purpose is to give the market early visibility of a possible change in control and to trigger any mandatory shareholder approval processes if the acquisition exceeds the 25% threshold. The filing therefore signals that Swapan Khandelwal’s share purchase is material enough to warrant regulatory notice, even though the exact size of the stake is not disclosed.

Key facts at a glance

Why this matters for investors

The disclosure alerts investors that a potentially significant shareholder is building a position in Goldline Pharmaceutical. If the acquisition eventually crosses the 25% holding limit, the company will be required to call a shareholder meeting to obtain approval for any further increase, which could affect voting dynamics and future strategic decisions. Until the exact size of the stake is known, the immediate impact on share dilution or control remains uncertain. Investors should monitor subsequent filings for additional information on the size of the acquisition and any related shareholder approvals.

Conclusion

Goldline Pharmaceutical has complied with SEBI’s requirement to disclose a substantial share acquisition by Swapan Khandelwal on 24 June 2026. The filing does not reveal the scale of the transaction, leaving materiality open-ended. Further disclosures are expected if the stake reaches regulatory thresholds or if the acquirer seeks to increase its holding.